ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 1854

What Is Our Regional Delay to Diagnosis in Patients with Axial Spondyloarthropathy – Are We Hitting the Target? Data from a Multi-centre UK Patient Cohort
Abstract Number: 1855

Using a Whole-population Approach to Help Design More Effective and Efficient Healthcare Services for People with Fibromyalgia
Abstract Number: 1856

Improving Recombinant Zoster Vaccination Rates in Patients Receiving Immunosuppressive Therapy in the Rheumatology Clinic at the Orlando VA Healthcare System – a Quality Improvement Project
Abstract Number: 1857

More Than 50% of Rheumatoid Arthritis (RA) Patients with High or Moderate CDAI (clinical Disease Activity Index) Screen Positive on MDHAQ (multidimensional Health Assessment Questionnaire) Indices for FAST4 (fibromyalgia Assessment Screening Tool) And/or MDS2 (MDHAQ Depression Screen)
Abstract Number: 1858

How Did a Mandatory Switch Policy Influence the Uptake of Adalimumab Biosimilar and Other TNF Inhibitors?
Abstract Number: 1859

Examining Hydroxychloroquine Prescribing and SLE Damage in a Statewide Lupus Cohort
Abstract Number: 1860

Evaluation of the Receipt of Adequate Pharmacological and Psychological Treatment for Incident Depression and Anxiety in Individuals Living with Inflammatory Arthritis
Abstract Number: 1861

Efficacy of Non-pharmacological Interventions: A Systematic Review Informing the 2023 EULAR Recommendations for the Management of Fatigue in People with Inflammatory Rheumatic and Musculoskeletal Diseases
Abstract Number: 1862

Significant Overlap of Inflammatory and Degenerative Features on Spinal Imaging Among Patients with Degenerative Spinal Disease, Diffuse Idiopathic Skeletal Hyperostosis and Radiographic Axial Spondyloarthritis
Abstract Number: 1863

Immune-mediated Hypertrophic Pachymeningitis: Focusing on the Localization and Volume of Thickened Dura Mater Lesion
Abstract Number: 1864

Quantifying Inflammation: A Novel In-Vivo Total Body PET Imaging Tool to Determine the Kinetics of the Degree of Changes in Inflammation in Different Time Points
Abstract Number: 1865

Is Flexion Contracture in Knee Osteoarthritis Associated with MRI Pathologies over Time? Data from the Osteoarthritis Initiative
Abstract Number: 1866

MRI Confirms MRE Evidence of Sacroiliitis in Many with Crohn’s Disease: A Prospective Study for the Screening of axSpA in High-risk Populations
Abstract Number: 1867

Peripheral Volumetric Bone Mineral Density and Erosive Disease in Patients with Established Rheumatoid Arthritis: A Cross-Sectional Study Using High-Resolution Peripheral Quantitative Computed Tomography
Abstract Number: 1868

Long-term Efficacy of a 2-year MRI Treat-to-target Strategy on Radiographic Joint Damage Progression in Rheumatoid Arthritis Patients in Clinical Remission – Five Year Follow-up of the IMAGINE-RA Randomized Clinical Trial

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].